常规就诊前使用遗传聊天机器人评估遗传性癌症风险
这项多中心回顾性观察研究评估了基于网络的聊天机器人在常规女性健康就诊前自动分诊遗传性癌症风险的使用情况。在受邀的95166名患者中,61070名(64.2%)使用了聊天机器人,其中89.4%完成了癌症风险评估,71.4%完成了遗传检测教育部分。在54547名接受筛查的患者中,14,850名(约四分之一)符合美国国家综合癌症网络(NCCN)遗传检测标准;在1313名接受检测者中,73名(5.6%)携带致病性变异。
要点
- 聊天机器人可帮助在常规就诊前识别遗传性癌症综合征高风险患者。
- 在受邀患者中,64.2%(61070/95166)使用了聊天机器人,89.4%完成风险评估。
- 在54547名筛查患者中,14,850名(约四分之一)符合NCCN遗传检测标准。
核心结论
- 聊天机器人数字健康工具有助于在常规就诊前识别遗传性癌症综合征高风险患者。
- 该可扩展的干预措施能有效提供癌症风险评估、让患者接触教育信息并促进预防性遗传检测的路径。
研究设计与样本
- 多中心、回顾性观察性研究,评估患者在常规就诊预约前使用基于网络的聊天机器人,以评估遗传性乳腺癌和卵巢癌、Lynch综合征及腺瘤性息肉病综合征的风险。
- 结局指标包括聊天机器人交互中风险评估和教育部分的采用与完成情况,以及根据美国国家综合癌症网络(NCCN)标准评估的遗传性癌症风险识别。
主要发现
- 在受邀的95166名患者中,61070名(64.2%)使用了临床聊天机器人。
- 在参与的患者中,89.4%完成了癌症风险评估,71.4%完成了遗传检测教育部分。
- 排除超过5分钟的不活动间隔后,平均使用时间为15.4分钟(标准差2小时56.2分钟)。
- 在提供相关信息的患者中,19.1%(10849/56656)报告个人癌症史,66.7%(36469/54652)报告家族癌症史。
- 在常规就诊前接受聊天机器人筛查的54547名患者中,14850名(约四分之一)符合NCCN遗传检测标准;在1313名接受检测者中,73名(5.6%)携带致病性变异。
关键数值与推荐
- 在54547名筛查患者中,14850名符合NCCN遗传检测标准。
- 在1313名接受检测者中,73名(5.6%)携带致病性变异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine user uptake and experience with a clinical chatbot that automates hereditary cancer risk triage by collecting personal and family cancer history in routine women's health care settings. METHODS: We conducted a multicenter, retrospective observational study of patients who used a web-based chatbot before routine care appointments to assess their risk for hereditary breast and ovarian cancer, Lynch syndrome, and adenomatous polyposis syndromes. Outcome measures included uptake and completion of the risk-assessment and educational section of the chatbot interaction and identification of hereditary cancer risk as evaluated against National Comprehensive Cancer Network criteria. RESULTS: Of the 95,166 patients invited, 61,070 (64.2%) engaged with the clinical chatbot. The vast majority completed the cancer risk assessment (89.4%), and most completed the genetic testing education section (71.4%), indicating high acceptability among those who opted to engage. The mean duration of use was 15.4 minutes (SD 2 hours, 56.2 minutes) when gaps of inactivity longer than 5 minutes were excluded. A personal history of cancer was reported by 19.1% (10,849/56,656) and a family history of cancer was reported by 66.7% (36,469/54,652) of patients who provided the relevant information. One in four patients (14,850/54,547) screened with the chatbot before routine care appointments met National Comprehensive Cancer Network criteria for genetic testing. Among those who were tested, 5.6% (73/1,313) had a disease-causing pathogenic variant. CONCLUSION: A chatbot digital health tool can help identify patients at high risk for hereditary cancer syndromes before routine care appointments. This scalable intervention can effectively provide cancer risk assessment, engage patients with educational information, and facilitate a path toward preventive genetic testing. FUNDING SOURCE: Implementation of the chatbot in clinics was funded by industry support from commercial genetic testing laboratories Ambry, Invitae, and Progenity.
引用
- Nazareth S, Hayward L, Simmons E, et al. Hereditary Cancer Risk Using a Genetic Chatbot Before Routine Care Visits. Obstet Gynecol. 2021. PMID: 34735417. doi:10.1097/AOG.0000000000004596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。